Decreased C-MYC and BCL2 expression correlates with methylprednisolone- mediated inhibition of Raji lymphoma growth

Biochemical and Molecular Medicine

Volumn 60, Issue 2, 1997, Pages 108-115

  Morris, Geoffrey ^a   Denardo, Sally J ^a   Denardo, Gerald L ^a   Leshchinsky, Tatiana ^a   Wu, Biao ^a   Mack, Philip C ^a   Winthrop, Michelle D ^a   Gumerlock, Paul H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; METHYLPREDNISOLONE SODIUM SUCCINATE; PROTEIN BCL 2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOMA; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE C MYC; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 0031128329     PISSN: 10773150     EISSN: None     Source Type: Journal    
DOI: 10.1006/bmme.1997.2568     Document Type: Article

References (64)

1. Parker S L, Tong T, Bolden S, Wingo P A. Cancer statistics, 1996. CA Cancer J Clin. 46:1996;5-27.
2. Cantor K P, Fraumeni J F. Distribution of non-Hodgkin's lymphoma in the United States between 1950 and 1975. Cancer Res. 40:1980;2645-2652.
3. Longo D L, Maunch P, DeVita V T Jr., Urba W J, Jaffe E S. Lymphocytic lymphomas. Cancer: Principles & Practice of Oncology. 1993;Lippincott, Philadelphia. p. 1859-1927.
4. Thulasi R, Harbour D V, Thompson E B. Suppression of c-myc. J Biol Chem. 268:1993;18306-18312.
5. Schrek R. Cytotoxicity of adrenal cortex hormones on normal and malignant lymphocytes of man and rat. Proc Soc Exp Biol Med. 108:1961;328-332.
6. Schrek R. Prednisolone sensitivity and cytology of viable lymphocytes as tests for chronic lymphocytic leukemia. J Natl Cancer Inst. 33:1964;837-847.
7. Haynes R C Jr. Adrenocorticotropic hormone: Adrenocortical steroids and their synthetic analogs: Inhibitors of the synthesis and actions of adrenocortical hormones. Gilman A G. The Pharmacological Basis of Therapeutics. 1990;1431-1462 Pergamon, New York.
8. DeNardo G L, Lewis J P, DeNardo S J, O'Grady L F. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer. 73:1994;1425-1432.
9. Juweid M, Sharkey R M, Markowitz A, Behs T, Swayne L C, Dunn R, Hansen H J, Shevitz J, Leung S O, Rubin A D, Herskovic T, Hanley D, Goldberg D M. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 55:1995;5899s-5907s.
10. 131. N Engl J Med. 329:1993;459-465.
11. Levy R, Miller R A. Antibodies in cancer therapy. DeVita V T Jr., Hellman S, Rosenberg S A. Biologic Therapy of Cancer. 1991;512-522 Lippincott, Philadelphia.
12. Lewis J P, DeNardo G L, DeNardo S J. Radioimmunotherapy of lymphoma: A UC Davis experience. Hybridoma. 14:1995;115-120.
13. 131. Lancet. 346:1995;336-340.
14. Vitetta E S, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghettie V, Uhr J W, Thorpe P E. Phase I immunotoxin trial in patients with B cell lymphoma. Cancer Res. 51:1991;4052-4058.
15. Vriesendorp H M, Herpst J M, Germack M A, Klein J L, Leichner P K, Loudenslager D M. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease including Radiation Therapy Oncology Group 87-01. J Clin Oncol. 9:1991;918-928.
16. Waldmann T A. Lymphokine receptors: A target for immunotherapy of lymphomas. Ann Oncol. 5:1994;S13-17.
17. Kelly K. The regulation and expression of c-myc in normal and malignant cells. Annu Rev Immunol. 4:1986;321.
18. Karn J, Watson J V, Lowe A D, Green S M, Vedeckis W. Regulation of cell cycle duration by c-myc levels. Oncogene. 4:1989;773-787.
19. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S. Translocation of the c-myc. Proc Natl Acad Sci USA. 79:1982;7837-7841.
20. Battey J, Moulding C, Taub R, Murphy W, Stewart T, Potter H. The humanc-myc. Cell. 34:1983;779-787.
21. Cole M D. D. Themyc. Annu Rev Genet. 20:1986;361-384.
22. Lombardi L, Newcomb E W, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: Expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell. 49:1987;161-170.
23. Oswald F, Lovec H, Moroy T, Lipp M. E2F-dependent regulation of human MYC:Trans. Oncogene. 9:1994;2029-2036.
24. Cooper G M. Oncogenes. 1990;Jones & Bartlett, Boston.
25. 01. Nature. 328:1987;445-449.
26. Pulvertaft R JV. Cytology of Burkitt's tumor (African lymphoma). Lancet. 1:1964;238-240.
27. G, L, DeNardo, S, J, DeNardo, C, F, Meares, D, Kukis, H, Diril, M, J, McCall, et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma, Antibody Immunoconj Radiopharmacol, 4, 777, 785.
28. Hamlyn P H, Rabbitts T H. Translocation joins c-myc and immunoglobulin G1 genes in a Burkitt lymphoma revealing a third exon in the c-myc oncogene. Nature. 304:1983;135-139.
29. Amati B, Littlewood T D, Evan G I, Land H. The cMyc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 12:1993;5083-5087.
30. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science. 265:1994;2091-2093.
31. Ewen M E, Sluss H K, Whitehouse L L, Livingston D M. TGFβ inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell. 74:1993;1009-1020.
32. Alexandrow M G, Moses H L. Transforming growth factor β and cell cycle regulation. Cancer Res. 55:1995;1452-1457.
33. Laiho M, DeCaprio J A, Ludlow J W, Livingston D M, Massague J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell. 62:1990;175-185.
34. Bursch W, Oberhammer F, Jirtle R L, Askari M, Sedivy R, Grasl-Kraupp B, Purchio A F, Schulte-Hermann R. Transforming growth factor-β as a signal for induction of cell death by apoptosis. Br J Cancer. 67:1993;531-536.
35. Kyprianou N, English H F, Davidson N E, Isaacs J T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 51:1991;162-166.
36. DeNardo S J, Gumerlock P H, Winthrop M D, Mack P C, Chi S-G, Lamborn K R. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis related messenger RNA expression. Cancer Res. 55:1995;5837s-5841s.
37. Vaux D, Cory S, Adams J. BCL2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442.
38. Nunez G, London L, Hockenberry D, Alexander M, McKearn J P, Korsmeyer S J. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol. 144:1990;3602-3610.
39. Tsujimoto Y. Overexpression of the human Bcl-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci USA. 86:1989;1958-1962.
40. McDonnell T J, Deane N, Platt F M, Nunez G, Jaeger U, McKearn J P, Korsmeyer S J. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 57:1989;79-88.
41. Tsujimoto Y, Cossman J, Jaffe E, Croce C. Involvement of thebcl-2. Science. 228:1985;1440-1443.
42. Cleary M L, Smith S D, Sklar J. Cloning and structural analysis of cDNAs forbclbcl. Cell. 47:1986;19-28.
43. Chen-Levy Z, Nourse J, Cleary M L. Thebcl. Mol Cell Biol. 9:1989;701-710.
44. Miyashita T, Harigai M, Hanada M, Reed J C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:1994;3131-3135.
45. Miyashita T, Krajewski S, Krajewska M, Wang H G, Lin H K, Liebermann D A, Hoffman B, Reed J C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
46. Harper J W, Adami G R, Wei N, Keyomarsi K, Elledge S J. The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
47. Chen J, Jackson P K, Kirschner M W, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature. 374:1995;386-388.
48. El-Deiry W F, Tokino T, Velculescu V E, Levy D B, Parsons R, Trent J M, Lin D, Mercer W E, Kinzler K W, Vogelstein B. WAF1, Cell. 75:1993;817-825.
49. Xiong Y, Hannon G J, Zhang H, Casso D, Kobyashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
50. 1. Cancer Res. 54:1994;1169-1174.
51. Lowe S W, Ruley H E, Jacks T, Housman D E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
52. Gaidano G, Ballerini P, Gong J Z, Inghirami G, Neri A, Newcomb E W, Magrath I T, Knowles D M, Dalla-Favera R. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 88:1991;5413-5417.
53. Duthu A, Debuire B, Romano J, Ehrhart J C, Fiscella M, May E, Appella E, May P. p53 mutations in Raji cells: Characterization and localization relative to other Burkitt's lymphomas. Oncogene. 7:1992;2161-2167.
54. Smith M L, Chen I-T, Zhan Q, Bae I, Chen C-Y, Gilmer T M, Kastan M B, O'Connor P M, Fornace A J Jr. Interaction of the p53-regulating protein Gadd45 with proliferating cell nuclear antigen. Science. 266:1994;1376-1380.
55. Hollander M C, Alamo I, Jackman J, Wang M G, McBride O W, Fornace A J. Analysis of the mammaliangadd45. J Biol Chem. 268:1993;24385-24393.
56. Zhan Q, Carrier F, Fornace A J. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol. 13:1993;4242-4250.
57. Zhan Q, Bae I, Kastan M B, Fornace A J. The p53-dependent gamma-ray response ofGADD45. Cancer Res. 54:1994;2755-2760.
58. Kastan M B, Zhan Q, El-Deiry W S, Carrier F, Jacks T, Walsh W V, Plunkett B S, Vogelstein B, Fornace A J Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
59. Gumerlock P H, Edwards B F, Deitch A D, Meyers F J. Human renal clear cell carcinoma: Establishment and characterization of a new cell line (G-2101). In Vitro Cell Dev Biol. 24:1988;429-434.
60. Borchers H, Meyers F J, Gumerlock P H, Stewart S L, deVere White R W. nm23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: Altered expression in combined androgen blockaded carcinomas. J Urol. 155:1996;2080-2084.
61. Fishman J R, Gumerlock P H, Meyers F J, deVere White R W. Quantitation of NM23 expression in human prostate tissues. J Urol. 152:1994;202-207.
62. Chi S-G, deVere White R W, Meyers F J, Siders D B, Lee F, Gumerlock P H. p53. J Natl Cancer Inst. 86:1994;926-933.
63. Madewell B R, Gumerlock P H, Saunders K A, Meyers F J, Kraegel S A, Kawasaki E S. Canine and bovineRAS. Anticancer Res. 9:1989;1743-1750.
64. Saunders K A, Madewell B R, Oreffo V IC, Kraegel S A, Gumerlock P H. Nucleotide sequence of canine c-N-ras: Am Vet Med Assoc. 53:1992;600-603.